会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Process for sexing cow embryos
    • 性交奶牛胚胎的过程
    • US5876942A
    • 1999-03-02
    • US899811
    • 1997-07-24
    • Winston Teng-Kuei ChengChuan-Mu ChenChe-Lin HuChih-Hua WangKong-Bung Choo
    • Winston Teng-Kuei ChengChuan-Mu ChenChe-Lin HuChih-Hua WangKong-Bung Choo
    • C12Q1/68C07H21/02C07H21/04
    • C12Q1/6879
    • A rapid, highly reproducible and sensitive technique has been successfully developed for sexing the cow embryos, by method of polymerase chain reaction (PCR) against the amelogenin (bAML) genes located on both X- and Y-chromosomes of the Holstein dairy cattle. Results from DNA sequence analysis showed that there was only 45% homology between the intron 5 of AMLX and AMLY genes. Based on these sequences a pair of sex-specific primers, pbAML5XY(+) and pbAML5XY (-),were designed allowing to amplify a single fragment of 476-bp from the female cattle and two fragments of 476-bp and 341-bp from the male ones, respectively. The most important feature is that the precise sensitivity of sex-determination was confirmed to be reached as minimum template as trace amount of genomic DNA content in either a single lymphocyte or a single blastomere isolated from cow embryo at day-6 to day-7. Moreover, neither those of complicated procedures for purifying the DNA prior the PCR nor any extra pair of primers for serving as internal control is thought to be essential and the sex-determination of over hundred embryos can be completed at once within 4hrs.
    • 通过聚合酶链反应(PCR)对位于荷斯坦奶牛的X射线和Y染色体上的牙釉蛋白(bAML)基因的方法,已经成功开发了快速,高度重现和敏感的技术,用于性别雌性胚胎。 DNA序列分析结果表明,AMLX的内含子5与AMLY基因之间只有45%的同源性。 基于这些序列,设计了一对性别特异性引物pbAML5XY(+)和pbAML5XY( - ),从而扩增了来自雌性牛的476-bp的单个片段和476bp和341bp的两个片段 男性分别。 最重要的特征是确定了在第6天至第7天从单纯淋巴细胞或从胚胎中分离的单个卵裂球中的最小模板作为最小模板作为痕量的基因组DNA含量。 此外,在PCR前纯化DNA的复杂程序和用作内部对照的任何额外的引物对都不被认为是至关重要的,并且可以在4小时内立即完成100多个胚胎的性别测定。
    • 5. 发明授权
    • Transgenic mammal secreting B-domain deleted human FVII in its milk
    • 转基因哺乳动物在其牛奶中分泌B结构域缺失的人FVII
    • US07667089B2
    • 2010-02-23
    • US10820777
    • 2004-04-09
    • Winston T. K. ChengChuan-Mu ChenShwu-Wha LinChih-Hong WangChih-Jen LinShinn-Chih Wu
    • Winston T. K. ChengChuan-Mu ChenShwu-Wha LinChih-Hong WangChih-Jen LinShinn-Chih Wu
    • C12P21/00A01K67/027C12N15/00
    • C12N15/8509A01K67/0275A01K2217/05A01K2267/01C07K14/755C12N2830/008
    • Hemophilia A is one of the major inherited bleeding disorders caused by a deficiency or abnormality in coagulation factor VIII (FVIII). Hemophiliacs have been treated with whole plasma or purified FVIII concentrates. The risk of transmitting blood-borne viruses and the cost of highly purified FVIII are the major factors that restrict prophylaxis in hemophilia therapy. One of the challenges created by the biotechnology revolution is the development of methods for the economical production of highly purified proteins in large scales. The present invention provides improved mammary expression cassettes useful for the expression of genes at high levels in the milk of transgenic animals. In particular, the present invention provides recombinant signal peptide sequences derived from a-lactalbumin and aS1-casein milk genes suitable for leading protein secretion in the mammary gland. These gene cassettes are capable of delivering different transgenic constructs which result in the production of full-length or B domain-deleted therapeutic levels of biologically active human FVIII in the transgenic animals in vivo. Within the scope of the invention are also method for producing the transgenic non-human mammal, such as mouse, rat, rabbit, goat, sheep, pig and bovine species, capable of expressing human FVIII, and methods of making milk and methods of identifying protein from the transgenic milk.
    • 血友病A是凝血因子VIII(FVIII)缺乏或异常引起的主要遗传性出血性疾病之一。 已经用全血浆或纯化的FVIII浓缩物治疗血友病患者。 传播血源性病毒的风险和高度纯化的FVIII的成本是限制血友病治疗预防的主要因素。 生物技术革命带来的挑战之一是开发大规模经济生产高纯度蛋白质的方法。 本发明提供了可用于在转基因动物的牛奶中高水平表达基因的改进的乳腺表达盒。 特别地,本发明提供了衍生自α-乳白蛋白的重组信号肽序列和适合于在乳腺中引导蛋白质分泌的α1酪蛋白乳基因。 这些基因盒能够递送不同的转基因构建体,其导致在转基因动物体内产生全长或B结构域缺失的生物活性人类FVIII的治疗水平。 在本发明的范围内,也是用于生产能够表达人FVIII的转基因非人哺乳动物如小鼠,大鼠,兔,山羊,绵羊,猪和牛物种的方法,以及制备牛奶的方法和鉴定方法 来自转基因乳的蛋白质。
    • 8. 发明申请
    • Method for producing biologically active human factor VIII in the milk of transgenic animals driven by mammary-specific expression cassettes
    • 在乳腺特异性表达盒驱动的转基因动物的乳中生产生物活性人因子VIII的方法
    • US20050229261A1
    • 2005-10-13
    • US10820777
    • 2004-04-09
    • Winston ChengChuan-Mu ChenShwu-Wha LinChih-Hong WangChih-Jen LinShinn-Chih Wu
    • Winston ChengChuan-Mu ChenShwu-Wha LinChih-Hong WangChih-Jen LinShinn-Chih Wu
    • A01K67/027C07K14/755C12N15/85
    • C12N15/8509A01K67/0275A01K2217/05A01K2267/01C07K14/755C12N2830/008
    • Hemophilia A is one of the major inherited bleeding disorders caused by a deficiency or abnormality in coagulation factor VIII (FVIII). Hemophiliacs have been treated with whole plasma or purified FVIII concentrates. The risk of transmitting blood-borne viruses and the cost of highly purified FVIII are the major factors that restrict prophylaxis in hemophilia therapy. One of the challenges created by the biotechnology revolution is the development of methods for the economical production of highly purified proteins in large scales. The present invention provides improved mammary expression cassettes useful for the expression of genes at high levels in the milk of transgenic animals. In particular, the present invention provides recombinant signal peptide sequences derived from a-lactalbumin and aS1-casein milk genes suitable for leading protein secretion in the mammary gland. These gene cassettes are capable of delivering different transgenic constructs which result in the production of full-length or B domain-deleted therapeutic levels of biologically active human FVIII in the transgenic animals in vivo. Within the scope of the invention are also method for producing the transgenic non-human mammal, such as mouse, rat, rabbit, goat, sheep, pig and bovine species, capable of expressing human FVIII, and methods of making milk and methods of identifying protein from the transgenic milk.
    • 血友病A是凝血因子VIII(FVIII)缺乏或异常引起的主要遗传性出血性疾病之一。 已经用全血浆或纯化的FVIII浓缩物治疗血友病患者。 传播血源性病毒的风险和高度纯化的FVIII的成本是限制血友病治疗预防的主要因素。 生物技术革命带来的挑战之一是开发大规模经济生产高纯度蛋白质的方法。 本发明提供了可用于在转基因动物的牛奶中高水平表达基因的改进的乳腺表达盒。 特别地,本发明提供了衍生自α-乳白蛋白的重组信号肽序列和适合于在乳腺中引导蛋白质分泌的α1酪蛋白乳基因。 这些基因盒能够递送不同的转基因构建体,其导致在转基因动物体内产生全长或B结构域缺失的生物活性人类FVIII的治疗水平。 在本发明的范围内,也是用于生产能够表达人FVIII的转基因非人哺乳动物如小鼠,大鼠,兔,山羊,绵羊,猪和牛物种的方法,以及制备牛奶的方法和鉴定方法 来自转基因乳的蛋白质。
    • 9. 发明授权
    • Method for manufacturing animal model for researching pulmonary tumor and use thereof
    • 制造肺肿瘤研究动物模型的方法及其应用
    • US08247644B2
    • 2012-08-21
    • US12828786
    • 2010-07-01
    • Chuan-Mu Chen
    • Chuan-Mu Chen
    • A01K67/033A01K67/00C12N15/00
    • A01K67/0275A01K2217/052A01K2227/105A01K2267/03A01K2267/0325
    • The present invention is a method for manufacturing an animal model for researching a pulmonary tumor and a use thereof. A transgenic non-human animal of the present invention is prepared by embryonic gene microinjection and possesses a tissue-specific expression of vascular endothelial growth factor A165 (VEGF-A165) in lung. Through the expression of vascular endothelial growth factor A165, the lung cells in the transgenic non-human animal of the present invention have inflammatory, vascularogenesis and angiogenesis responses or induce lung tumors. Thus, the non-human animal of the present invention can serve as an animal model for analyzing the regulation and the anti-tumor drugs screening of pulmonary adenocarcinoma.
    • 本发明是一种用于制造用于研究肺肿瘤的动​​物模型及其用途的方法。 通过胚胎基因显微注射制备本发明的转基因非人动物,并且在肺中具有血管内皮生长因子A165(VEGF-A165)的组织特异性表达。 通过血管内皮生长因子A165的表达,本发明的转基因非人动物中的肺细胞具有炎性,血管发生和血管生成反应或诱导肺肿瘤。 因此,本发明的非人动物可以作为用于分析肺腺癌的调节和抗肿瘤药物筛选的动物模型。